PMID- 22940464
OWN - NLM
STAT- MEDLINE
DCOM- 20130715
LR  - 20220321
IS  - 1872-6623 (Electronic)
IS  - 0304-3959 (Print)
IS  - 0304-3959 (Linking)
VI  - 153
IP  - 11
DP  - 2012 Nov
TI  - Effects of gonadal hormones on the peripheral cannabinoid receptor 1 (CB1R) 
      system under a myositis condition in rats.
PG  - 2283-2291
LID - 10.1016/j.pain.2012.07.037 [doi]
AB  - In this study, we assessed the effects of peripherally administered cannabinoids 
      in an orofacial myositis model, and the role of sex hormones in cannabinoid 
      receptor (CBR) expression in trigeminal ganglia (TG). Peripherally administered 
      arachidonylcyclopropylamide (ACPA), a specific CB1R agonist, significantly 
      attenuated complete Freund's adjuvant (CFA)-induced mechanical hypersensitivity 
      in the masseter muscle in male rats. The ACPA effect was blocked by a local 
      administration of AM251, a specific CB1R antagonist, but not by AM630, a specific 
      CB2R antagonist. In female rats, a 30-fold higher dose of ACPA was required to 
      produce a moderate reduction in mechanical hypersensitivity. CFA injected in 
      masseter muscle significantly upregulated CB1R mRNA expression in TG in male, but 
      not in female, rats. There was a close correlation between the CB1R mRNA levels 
      in TG and the antihyperalgesic effect of ACPA. Interleukin (IL)-1beta and IL-6, 
      which are elevated in the muscle tissue following CFA treatment, induced a 
      significant upregulation of CB1R mRNA expression in TG from male rats. The 
      upregulation of CB1R was prevented in TG cultures from orchidectomized male rats, 
      which was restored by the application of testosterone. The cytokines did not 
      alter the CB1R mRNA level in TG from intact as well as ovariectomized female 
      rats. Neither estradiol supplement nor estrogen receptor blockade had any effects 
      on CB1R expression. These data indicate that testosterone, but not estradiol, is 
      required for the regulation of CB1Rs in TG under inflammatory conditions, which 
      provide explanations for the sex differences in the antihyperalgesic effects of 
      peripherally administered cannabinoids.
CI  - Copyright (c) 2012 International Association for the Study of Pain. Published by 
      Elsevier B.V. All rights reserved.
FAU - Niu, Katelyn Y
AU  - Niu KY
AD  - Program in Neuroscience, Department of Neural and Pain Sciences, University of 
      Maryland School of Dentistry, Baltimore, MD 21201, USA.
FAU - Zhang, Youping
AU  - Zhang Y
FAU - Ro, Jin Y
AU  - Ro JY
LA  - eng
GR  - F30 DE020988/DE/NIDCR NIH HHS/United States
GR  - R01 DE019448/DE/NIDCR NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20120831
PL  - United States
TA  - Pain
JT  - Pain
JID - 7508686
RN  - 0 (Cnr2 protein, rat)
RN  - 0 (Estrogens)
RN  - 0 (Receptor, Cannabinoid, CB1)
RN  - 0 (Receptor, Cannabinoid, CB2)
RN  - 3XMK78S47O (Testosterone)
SB  - IM
MH  - Animals
MH  - Disease Models, Animal
MH  - Estrogens/*physiology
MH  - Facial Pain/drug therapy/*physiopathology
MH  - Female
MH  - Male
MH  - Myositis/drug therapy/*physiopathology
MH  - Primary Cell Culture
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptor, Cannabinoid, CB1/agonists/antagonists & inhibitors/*genetics
MH  - Receptor, Cannabinoid, CB2/agonists/antagonists & inhibitors/physiology
MH  - Testosterone/*physiology
PMC - PMC3578305
MID - NIHMS399508
EDAT- 2012/09/04 06:00
MHDA- 2013/07/17 06:00
PMCR- 2013/11/01
CRDT- 2012/09/04 06:00
PHST- 2012/03/19 00:00 [received]
PHST- 2012/07/31 00:00 [revised]
PHST- 2012/07/31 00:00 [accepted]
PHST- 2012/09/04 06:00 [entrez]
PHST- 2012/09/04 06:00 [pubmed]
PHST- 2013/07/17 06:00 [medline]
PHST- 2013/11/01 00:00 [pmc-release]
AID - 00006396-201211000-00020 [pii]
AID - 10.1016/j.pain.2012.07.037 [doi]
PST - ppublish
SO  - Pain. 2012 Nov;153(11):2283-2291. doi: 10.1016/j.pain.2012.07.037. Epub 2012 Aug 
      31.